Stock 300558 BETTA PHARMACEUTICALS CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Betta Pharmaceuticals Co., Ltd.

Equities

300558

CNE100002DD9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
41.59 CNY +2.59% Intraday chart for Betta Pharmaceuticals Co., Ltd. +8.59% -19.32%
Apr. 19 Betta Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Jan. 04 C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd. CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 26,346 44,361 33,154 20,525 21,573 17,405 - -
Enterprise Value (EV) 1 26,468 43,015 32,367 21,551 23,243 19,363 19,024 17,405
P/E ratio 115 x 72.1 x 86.8 x 141 x 62.1 x 35.1 x 28.6 x -
Yield 0.29% 0.29% 0.31% 0.14% 0.33% 0.66% 0.64% -
Capitalization / Revenue 17 x 23.7 x 14.8 x 8.64 x 8.78 x 5.68 x 4.45 x 3.95 x
EV / Revenue 17 x 23 x 14.4 x 9.07 x 9.46 x 6.32 x 4.87 x 3.95 x
EV / EBITDA 64.6 x 51.4 x 57.3 x 63.1 x 39.7 x 15.6 x 15.6 x -
EV / FCF - -1,124 x - - -146 x 15.2 x 11.8 x 8.79 x
FCF Yield - -0.09% - - -0.69% 6.6% 8.5% 11.4%
Price to Book 10.7 x 10.7 x 7.27 x - 4.11 x 3.09 x 2.9 x -
Nbr of stocks (in thousands) 401,000 413,163 415,305 416,583 418,486 418,486 - -
Reference price 2 65.70 107.4 79.83 49.27 51.55 41.59 41.59 41.59
Announcement Date 2/27/20 3/25/21 4/6/22 4/23/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 1,554 1,870 2,246 2,377 2,456 3,066 3,909 4,402
EBITDA 1 410 836.5 564.7 341.4 585.4 1,238 1,220 -
EBIT 1 266.6 680.7 395.6 94.8 270.1 545.3 643.4 -
Operating Margin 17.15% 36.39% 17.61% 3.99% 11% 17.79% 16.46% -
Earnings before Tax (EBT) 1 266.5 666.7 389.9 87.57 322.1 517.8 620.7 -
Net income 1 230.8 606.4 383.1 145.4 348 496.8 608.3 -
Net margin 14.85% 32.42% 17.06% 6.12% 14.17% 16.21% 15.56% -
EPS 2 0.5700 1.490 0.9200 0.3500 0.8300 1.185 1.455 -
Free Cash Flow 1 - -38.26 - - -159.6 1,278 1,617 1,980
FCF margin - -2.05% - - -6.5% 41.69% 41.37% 44.98%
FCF Conversion (EBITDA) - - - - - 103.27% 132.55% -
FCF Conversion (Net income) - - - - - 257.23% 265.83% -
Dividend per Share 2 0.1900 0.3100 0.2500 0.0700 0.1700 0.2750 0.2667 -
Announcement Date 2/27/20 3/25/21 4/6/22 4/23/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3
Net sales 1 521.4 584.7 668.6 409.4 713.9 782.3 729.7 412.6 735.8 770.4 783.6
EBITDA - - - - - - - - - - -
EBIT 1 12.12 97.04 -21.65 18.6 0.8041 81.58 165.7 - 108.4 85.83 122.2
Operating Margin 2.32% 16.6% -3.24% 4.54% 0.11% 10.43% 22.71% - 14.73% 11.14% 15.6%
Earnings before Tax (EBT) - - - - - - - - - - -
Net income - - - - - - - - - - -
Net margin - - - - - - - - - - -
EPS 2 0.1000 0.2000 0.0300 0.0200 0.1000 0.2300 0.3700 0.1000 0.2300 0.1900 -
Dividend per Share - - - - - - - - - - -
Announcement Date 4/6/22 4/26/22 8/24/22 10/28/22 4/23/23 8/25/23 10/24/23 4/19/24 4/19/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 122 - - 1,026 1,670 1,958 1,619 -
Net Cash position 1 - 1,346 787 - - - - -
Leverage (Debt/EBITDA) 0.2984 x - - 3.005 x 2.853 x 1.582 x 1.327 x -
Free Cash Flow 1 - -38.3 - - -160 1,278 1,617 1,980
ROE (net income / shareholders' equity) 9.84% 21.3% 8.8% - 6.89% 8.7% 10.1% -
ROA (Net income/ Total Assets) 6.08% 13% - - - 5.2% 7% -
Assets 1 3,796 4,682 - - - 9,555 8,690 -
Book Value Per Share 2 6.140 10.00 11.00 - 12.50 13.50 14.30 -
Cash Flow per Share 2 1.380 1.560 1.260 - 2.180 2.190 0.2100 -
Capex 1 620 684 758 - 1,074 609 265 352
Capex / Sales 39.9% 36.59% 33.76% - 43.72% 19.87% 6.79% 8%
Announcement Date 2/27/20 3/25/21 4/6/22 4/23/23 4/19/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Betta Pharmaceuticals Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
41.59 CNY
Average target price
50.98 CNY
Spread / Average Target
+22.57%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.32% 2.34B
MERCK KGAA Stock Merck KGaA
+4.06% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.51% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-14.44% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+41.60% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+5.96% 3.85B
INDIVIOR PLC Stock Indivior PLC
+23.46% 2.38B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-27.04% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+7.97% 1.96B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300558 Stock
  4. Financials Betta Pharmaceuticals Co., Ltd.